This novel compound is currently undergoing laboratory investigation. The success of growth-hormone-receptor antagonists in treating unresolved acromegaly is very encouraging for speculating on ...

Peptides have gained significant attention in research due to their possible role in regulating various physiological ...

Macrilen (Macimorelin): AEterna Zentaris Macrilen (Macimorelin) is a medicine that treats adult growth hormone deficiency. Macimorelin works as a growth hormone secretagogue receptor agonist, which ...

GHI resulting from a genetic abnormality of the growth hormone receptor (GHR) is rare. In its most severe form, it is known as classical GHI syndrome (GHIS) or Laron syndrome, 1 which occurs ...

Discover the role of phytoestrogens, including soy, in menopause management and breast cancer prevention. Learn how these ...

Many of these OXT and vasopressin binding-independent activities have involved a parallel expansion on the roles of known cellular components; among these are β-arrestins, cholesterol, and steroid ...

The table below is a review of notable updates that occurred in December 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

2. Ovarian Cancer: Research indicates that a woman's chance of developing ovarian cancer may be influenced by hormonal ...

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs. those using a DPP-IV inhibitor. Women may have a lower risk for thyroid cancer ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.